Literature DB >> 15997013

Assessment of capacity to consent to research among older persons with schizophrenia, Alzheimer disease, or diabetes mellitus: comparison of a 3-item questionnaire with a comprehensive standardized capacity instrument.

Barton W Palmer1, Laura B Dunn, Paul S Appelbaum, Sunder Mudaliar, Leon Thal, Robert Henry, Shahrokh Golshan, Dilip V Jeste.   

Abstract

CONTEXT: Considerable discussion surrounds issues related to the capacities of neuropsychiatric patients to consent to research, yet few empirical investigations have directly compared decisional capacity among patients with a serious mental illness with that among patients with neurologic or medical conditions. Also, as requirements for formal assessment of decisional capacity are becoming more common, there is a clear need to identify efficient screening methods.
OBJECTIVES: To compare decisional capacity among 3 diagnostic groups, and to examine the degree to which impaired understanding can be detected with a brief set of screening questions.
SETTING: Outpatient veterans hospital clinic and university-based neuropsychiatric research centers. DESIGN/ PARTICIPANTS: Cross-sectional comparison of decisional capacity among older (>/=60 years) outpatients with schizophrenia (n = 35), mild to moderate Alzheimer disease (n = 30), and type 2 diabetes mellitus (n = 36), and determination of sensitivity and specificity of a screening measure. MAIN OUTCOME MEASURES: Three-item decisional capacity questionnaire and the MacArthur Competence Assessment Tool for Clinical Research.
RESULTS: Patients with diabetes mellitus performed the best on the capacity instruments, patients with Alzheimer disease had the worst performance, and patients with schizophrenia were intermediate. However, there was considerable heterogeneity within each group. Even within diagnostic groups, the level of cognitive functioning (measured with the Mini-Mental State Examination) was generally the best predictor of decisional capacity (particularly in the understanding component). The 3-item questionnaire was sensitive to impaired understanding as measured with the MacArthur Competence Assessment Tool for Clinical Research understanding subscale.
CONCLUSIONS: Decisional capacity differed among the 3 groups; there was considerable heterogeneity even within each diagnostic group, so individualized consideration of capacity may be warranted. The level of cognitive deficits is 1 potential marker of which participants should receive comprehensive capacity evaluations, but sensitive brief questionnaires targeting key aspects of disclosed information may also provide an effective means of screening for participants warranting comprehensive capacity evaluations.

Entities:  

Mesh:

Year:  2005        PMID: 15997013     DOI: 10.1001/archpsyc.62.7.726

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  66 in total

1.  Screening for understanding of research in the inpatient psychiatry setting.

Authors:  Norval J Hickman; Judith J Prochaska; Laura B Dunn
Journal:  J Empir Res Hum Res Ethics       Date:  2011-09       Impact factor: 1.742

2.  Capacity to make medical treatment decisions in multiple sclerosis: a potentially remediable deficit.

Authors:  Michael R Basso; Philip J Candilis; Jay Johnson; Courtney Ghormley; Dennis R Combs; Taeh Ward
Journal:  J Clin Exp Neuropsychol       Date:  2010-12       Impact factor: 2.475

3.  Protocol for an embedded pragmatic clinical trial to test the effectiveness of Aliviado Dementia Care in improving quality of life for persons living with dementia and their informal caregivers.

Authors:  Alycia A Bristol; Kimberly A Convery; Victor Sotelo; Catherine E Schneider; Shih-Yin Lin; Jason Fletcher; Randall Rupper; James E Galvin; Abraham A Brody
Journal:  Contemp Clin Trials       Date:  2020-04-19       Impact factor: 2.226

Review 4.  Emerging empirical evidence on the ethics of schizophrenia research.

Authors:  Laura B Dunn; Philip J Candilis; Laura Weiss Roberts
Journal:  Schizophr Bull       Date:  2005-10-19       Impact factor: 9.306

5.  Do human subject safeguards matter to potential participants in psychiatric genetic research?

Authors:  Laura Weiss Roberts; Jane Paik Kim; Tenzin Tsungmey; Laura B Dunn
Journal:  J Psychiatr Res       Date:  2019-06-08       Impact factor: 4.791

6.  A direct comparison of research decision-making capacity: schizophrenia/schizoaffective, medically ill, and non-ill subjects.

Authors:  Philip J Candilis; Kenneth E Fletcher; Cynthia M A Geppert; Charles W Lidz; Paul S Appelbaum
Journal:  Schizophr Res       Date:  2008-02       Impact factor: 4.939

7.  Determinants of Capacity to Consent to Research on Alzheimer's disease.

Authors:  Barton W Palmer; Alexandrea L Harmell; Luz L Pinto; Laura B Dunn; Scott Y H Kim; Shahrokh Golshan; Dilip V Jeste
Journal:  Clin Gerontol       Date:  2016-06-07       Impact factor: 2.619

8.  A Doctor is in the House: Stakeholder Focus Groups About Expanded Scope of Practice of Community Psychiatrists.

Authors:  Christina Mangurian; Chelsea Modlin; Lindsey Williams; Susan Essock; Nicholas S Riano; Martha Shumway; John W Newcomer; James W Dilley; Dean Schillinger
Journal:  Community Ment Health J       Date:  2017-11-28

9.  Ethics in Psychiatric Research: A Review of 25 Years of NIH-funded Empirical Research Projects.

Authors:  James Dubois; Holly Bante; Whitney B Hadley
Journal:  AJOB Prim Res       Date:  2011-12-06

10.  Worth the risk? Relationship of incentives to risk and benefit perceptions and willingness to participate in schizophrenia research.

Authors:  Laura B Dunn; Daniel S Kim; Ian E Fellows; Barton W Palmer
Journal:  Schizophr Bull       Date:  2008-02-14       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.